Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +37.38%
#3 Glidr Glidr +35.94%
#4 Walrus Walrus +22.68%
#5 Tutorial Tutorial +22.05%
#6 Codatta Codatta +16.69%
#7 Humanity Humanity +16.02%
#8 Ribbita by Virtuals Ribbita by Virtuals +14.73%
#9 Enso Enso +14.41%
#10 Cysic Cysic +12.50%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Rank in Stocks #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Share Price
$0.6
Last synced: 2024-08-14
Market Cap
$2.09M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
SG
Trade ASLAN Pharmaceuticals Limited (ASLN)

Category

Healthcare
P/B ratio for ASLAN Pharmaceuticals Limited (ASLN)
P/B ratio as of August 2026 TTM: -0.19
According to ASLAN Pharmaceuticals Limited latest financial reports and stock price the company's current price-to-book ratio (TTM) is -0.19. At the end of 2022 the company had a P/B ratio of 0.96.
P/B ratio history for ASLAN Pharmaceuticals Limited from 2014 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) -0.19 -11.57%
2023 -0.21 -121.55%
2022 0.96 135.76%
2021 0.41 -118.92%
2020 -2.15 -82.88%
2019 -12.58 -1,216.28%
2018 1.13 -10.51%
2017 1.26 11.69%
2016 1.13 -308.68%
2015 -0.54 496.91%
2014 -0.09 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -3,515.13%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -3,460.96%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -1,963.87%
BE